Clinical Trial Update: ADAs to Alemtuzumab

View source ↗

Summary

This clinical trial update reports on anti-drug antibodies (immunogenicity) observed with alemtuzumab in people with multiple sclerosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Lemtrada (alemtuzumab)

Snippet

Sponsor: Queen Mary University of London | Conditions: Multiple Sclerosis | Status: COMPLETED